Novartis India Appoints Dr. Chetan P. as Head of Medical, Regulatory and Pharmacovigilance

Novartis India has appointed Dr. Chetan P. as Head of Medical, Regulatory and Pharmacovigilance (PV), consolidating three compliance-critical functions under a single leadership mandate at a time when India's pharmacovigilance framework is under heightened regulatory scrutiny.

The combined remit spanning medical affairs, regulatory affairs, and PV reflects a structural approach increasingly adopted by MNC subsidiaries operating under CDSCO oversight, where signal detection, dossier management, and post-market safety reporting intersect with growing frequency. For regulatory affairs leads at India-based operations, the appointment signals that Novartis is treating these functions as an integrated compliance unit rather than parallel verticals.

India's PV environment has grown more demanding following the expansion of the Pharmacovigilance Programme of India (PvPI) and successive CDSCO guidance updates tightening adverse event reporting timelines and periodic safety update report (PSUR) submissions. An executive holding authority across all three domains is better positioned to align local safety data with global dossier requirements and respond to regulatory queries without cross-functional lag.

For QA directors and regulatory leads at competing MNC subsidiaries, the structural logic is worth examining: unified medical-regulatory-PV leadership compresses the decision chain between safety signal identification and regulatory action, a configuration that reduces exposure during inspections where documentation of signal-to-action timelines is reviewed.

Dr. Chetan P.'s specific background and prior roles were not disclosed in the source announcement; Novartis India has not issued additional commentary on the strategic rationale behind the appointment.

The appointment takes effect as CDSCO continues to refine its post-market surveillance expectations, making the scope of this role a measurable indicator of how Novartis India intends to resource its compliance obligations through the next regulatory cycle.

Source: Media4Growth via Indian Pharma Post, 17 August 2026.